Series A Completed
Solstice Oncology Series A
US$225m raised
Announced 9 Sep 2026
Investors
Investors
- Canaan
- RA Capital
- Forbion
Investors as the sources name them; a linked name has a FundComb profile.
- Company
- Solstice Oncology
- Stage
- Series A
- Amount raised
- US$225m
- Company based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
Similar rounds
- Emerald AI Series A Aug 2026 · US$150m · led by DCVC
- HIFI Series A Sep 2026 · US$37m · led by Left Lane Capital
- Mach9 Series A Oct 2026 · US$34m · led by Bessemer Venture Partners
- Arintra Series A Aug 2026 · US$25m · led by Peak XV Partners
- Vedana Therapeutics Series A Jun 2026 · US$46m · led by Canaan
Sources
- 9 Sep 2026 Transforming Early-Stage Colon Cancer Outcomes: Why We Invested in Solstice Oncology canaan.com